Analysis of tumor growth rate for radioiodine (RAI)-refractory differentiated thyroid cancer patients receiving placebo and/or sorafenib in the phase III DECISION study
Publication/Presentation Date
5-2015
Volume
33
Issue
15
Published In/Presented At
Disciplines
Medicine and Health Sciences
Department(s)
Hematology-Medical Oncology Division
Document Type
Article
COinS